摘要
背景:肾素血管紧张素系统(RAS)在炎症和纤维化中起重要作用。由血管紧张素转换酶(ACE),血管紧张素II(Ang II)和血管紧张素受体1(AT1)形成的RAS的经典轴线激活了与组织损伤,炎症和纤维化相关的几种细胞功能和分子信号通路。与此形成鲜明对比的是,由血管紧张素转换酶2(ACE2),血管紧张素(1-7)和Mas受体组成的RAS轴相对于炎性反应和组织纤维化发挥相反作用。 目的:在本次评估中,我们的目的是总结近期关于ACE2 / Ang-(1-7)/ Mas轴在基础研究,实验人类疾病和背景中的抗炎和抗纤维化作用的研究结果。临床研究。 结果:几项研究表明ACE2 /血管紧张素(1-7)/ Mas轴在人类疾病包括动脉粥样硬化,脑缺血,肥胖,慢性肾脏疾病,肝脏疾病和哮喘等实验模型中减少细胞因子释放并抑制组织纤维化信号通路。另一方面,临床研究提供的数据很少。 结论:实验研究明确支持ACE2 / Ang-(1-7)/ Mas轴的抗炎和抗纤维化作用。临床研究,特别是III期和IV期试验将有必要建立ACE2 / Ang-(1-7)/ Mas轴在控制不同人类疾病中的炎症中的治疗作用。
关键词: 血管紧张素(1-7),Mas,ACE2,血管紧张素II,炎症,细胞因子,白细胞,纤维化。
图形摘要
Current Drug Targets
Title:The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Volume: 18 Issue: 11
关键词: 血管紧张素(1-7),Mas,ACE2,血管紧张素II,炎症,细胞因子,白细胞,纤维化。
摘要: Background: The renin angiotensin system (RAS) plays an important role in inflammation and fibrosis. The classical axis of the RAS, formed by angiotensin converting en-zyme (ACE), angiotensin II (Ang II) and angiotensin receptor type 1 (AT1), activates several cell functions and molecular signaling pathways related to tissue injury, inflammation and fibrosis. In sharp contrast, the RAS axis composed by angiotensin converting enzyme 2 (ACE2), angiotensin-(1-7) and Mas receptor exerts opposite effects in relation to inflammatory response and tissue fibrosis.
Objective: In this review, we have the aim to summarize recent findings on the anti-inflammatory and anti-fibrogenic role of ACE2/Ang-(1-7)/Mas axis in the context of basic research, experimental human dis-eases and clinical studies. Results: Several studies showed that ACE2/Angiotensin-(1-7)/Mas axis reduces cytokine release and inhibits signaling pathways of tissue fibrosis in experimental models of human diseases including atherosclerosis, cerebral ischemia, obesity, chronic kidney disease, liver diseases and asthma. On the other hand, very few data was provided by clinical studies. Conclusion: Experimental studies clearly support the anti-inflammatory and anti-fibrotic effects of ACE2/ Ang-(1-7)/Mas axis. Clinical studies, especially phase III and IV trials, will be necessary to establish the therapeutic role of ACE2/Ang-(1-7)/Mas axis in controlling inflammation in different human diseases.Export Options
About this article
Cite this article as:
The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research, Current Drug Targets 2017; 18 (11) . https://dx.doi.org/10.2174/1389450117666160727142401
DOI https://dx.doi.org/10.2174/1389450117666160727142401 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Technological Innovations in Magnetic Resonance for Early Detection of Cardiovascular Diseases
Current Pharmaceutical Design Editorial[Hot Topic:Stem Cell Therapy for Cardiovascular Diseases:Are We Still at the Beginning of A Long Road?(Guest Editor:Lino M Goncalves)
Cardiovascular & Hematological Disorders-Drug Targets Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Cardiomyocyte-Specific TβR2 Knockout Mice are More Susceptible to Cardiac Hypertrophy Induced by Adrenergic Agonist Stimulation
Current Molecular Medicine Early Growth Response-1 (EGR-1) – A Key player in Myocardial Cell Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Restriction Factors Against Recombinant Adeno-associated Virus Vectormediated Gene Transfer in Dystrophin-deficient Muscles
Current Gene Therapy Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology New Insights in Research About Acute Ischemic Myocardial Injury and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure
Current Vascular Pharmacology Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
Current Cardiology Reviews Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Diagnosis and Prognosis of Fetal Cardiomyopathies: A Review
Current Pharmaceutical Design Anti-T. cruzi Agents: Our Experience in the Evaluation of More than Five Hundred Compounds
Mini-Reviews in Medicinal Chemistry TSH Variations in Chronic Heart Failure Outpatients: Clinical Correlates and Outcomes
Endocrine, Metabolic & Immune Disorders - Drug Targets New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents